| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789074 | IPSEN INC | Composition and method for muscle repair and regeneration |
Aug, 2031
(7 years from now) | |
| US9314439 | IPSEN INC | Composition and method for muscle repair and regeneration |
Aug, 2031
(7 years from now) | |
| US10292954 | IPSEN INC | Composition and method for muscle repair and regeneration |
Aug, 2031
(7 years from now) | |
| US11622959 | IPSEN INC | Methods for treating heterotopic ossification |
Jun, 2037
(13 years from now) | |
| US10864194 | IPSEN INC | Methods for treating heterotopic ossification |
Jun, 2037
(13 years from now) | |
Sohonos is owned by Ipsen Inc.
Sohonos contains Palovarotene.
Sohonos has a total of 5 drug patents out of which 0 drug patents have expired.
Sohonos was authorised for market use on 16 August, 2023.
Sohonos is available in capsule;oral dosage forms.
Sohonos can be used as reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva.
Drug patent challenges can be filed against Sohonos from 17 August, 2027.
The generics of Sohonos are possible to be released after 08 June, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-439) | Aug 16, 2030 |
| New Chemical Entity Exclusivity(NCE) | Aug 16, 2028 |
Drugs and Companies using PALOVAROTENE ingredient
NCE-1 date: 17 August, 2027
Market Authorisation Date: 16 August, 2023
Treatment: Reduction of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva
Dosage: CAPSULE;ORAL
SOHONOS family patents
